Iveric Bio (ISEE) PT Raised to $14 at Credit Suisse, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ISEE Hot Sheet
Price: $39.95 --0%
Rating Summary:
4 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
4 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $14.00 (from $13.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $340 at BMO Capital
- Apollo Global Management (APO) PT Lowered to $136 at TD Cowen
- Westpac Banking Corp. (WBC:AU) (WBK) PT Lowered to AUD41.50 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Credit Suisse, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
